Comparison of D2 versus D1 gastrectomy in Kashmiri patients in a tertiary care cancer centre

Mohamad Younis1*, Adfar Yousuf2, Syed Nisar Ahmad3, Ajay Vane1

1Department of Surgical Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Soura Srinagar, Jammu and Kashmir, India
2Department of Biotechnology, Sri Pratap College, Cluster University Srinagar Kashmir, Jammu and Kashmir, India
3Department Of Medical Oncology, Sher-i-Kashmir Institute of Medical Sciences, Soura Srinagar, Jammu and Kashmir, India

Received: 15 January 2022
Revised: 28 January 2022
Accepted: 31 January 2022

*Correspondence:
Dr. Mohamad Younis,
E-mail: younisamin@yahoo.co.in

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: The aim of this study was to compare the clinical outcomes, survival, morbidity and mortality of D1 and D2 gastrectomy in Kashmiri population in a high-volume tertiary care centre.

Methods: Data were collected retrospectively from the prospective database maintained by Department of Surgical Gastroenterology at SKIMS, Kashmir India. We did direct comparison of D1 and D2 gastrectomy in gastric cancer patients who underwent surgery between January 2016 to December 2021 and fulfilled the eligibility criteria. A total of 98 patients were included in the study of which 46 underwent a D1 gastrectomy and 52 underwent a D2 gastrectomy.

Results: Male-female ratio was 3:1 in both groups with a mean age of 61 years. There was no significant difference in terms of age or gender between D1 and D2 groups (p>0.05). The mean number of harvested lymph nodes (LN) was (7±1.9) in the D1 group compared to (27.6±10.1) the D2 group (p=0.001). Average hospital stay was comparable in both groups. The median survival was 26 months for the D2 and 19 months for the D1 group (p≤0.01). The survival in the D2 group was significantly higher than in the D1 group. There was no difference in postoperative complications between two groups in our study.

Conclusions: our study indicates that D2 gastrectomy should be the standard of treatment for advanced stage II /III disease as it improves the survival outcome in these patients without affecting overall hospital stay, morbidity and mortality.

Keywords: Gastric cancer, Kashmir, D1 and D2 gastrectomy, Survival

INTRODUCTION

Gastric cancer remains one of the most common and deadly cancers worldwide. Based on GLOBOCAN 2018 data, stomach cancer is the 5th most common neoplasm and the 3rd most deadly cancer, with an estimated 783,000 deaths in 2018. The incidence of gastric cancer varies in different parts of the world and among various ethnic groups. Gastric cancer (GC) is common in the northeast and southern parts of India, although incidence in India is low compared with western countries and China. Incidence of GC varies widely among the various regions within India due to diverse culture and related food habits. Kashmiri population a geographically and ethnically distinct population with special cultural and dietary habits. Kashmir has a high incidence of stomach cancers compared to rest of India. It is the third most common cancer in Kashmir and has shown a gradual increase during the last 5 years. Gastric cancer is an aggressive disease and a multidisciplinary approach has
been proven to improve the outcome for advanced-stage gastric cancer patients, but surgical resection offers the most effective therapy for those with curable disease. Lymphadenectomy plays a key role in the surgical strategy of gastric cancer, mostly because nodal metastases could occur in early stages of disease. However, the extent of lymph node resection for curative intent varies between surgeons and centres globally and within India. The lymph node status in gastric cancer is a key prognostic factor in patient survival. There has been debate concerning the extent of lymph node dissection performed between western and eastern countries with eastern countries supporting D2 lymphadenectomy and western studies revealing arguable results. The Unit Kingdom (UK) MRC-STO1 trial and the Dutch DGCT trial didn’t report any statistically significant difference in survival, but a significantly higher mortality/ mortality in the D2 group compared to D1. Nevertheless, a 15-year follow-up of the same Dutch trial demonstrated an improved local regional recurrence and lower gastric cancer-related deaths after a D2 resection. The Italian gastric cancer study group (ICGCSIG) did not find a significant difference in overall 5-year survival between D1 and D2 patients; nevertheless, a subgroup investigation indicated a tendency towards enhanced survival for T2-T4 tumors and node-positive disease in D2 dissection. In the light of good survival outcomes after D2 dissection in Japan, gastrectomy with D2 dissection is becoming increasingly acceptable in Western countries. The latest national comprehensive cancer network guidelines for gastric cancer stated that D2 dissection should be considered as a recommended but not a required procedure. Lately, there is increasing consensus on a D2 lymphadenectomy with spleen and pancreas preservation and has become the standard of care, mostly in European centers. In Kashmir valley gastric cancer is a high incidence cancer but there is a paucity of data on gastrectomy outcomes of D1 and D2 lymphadenectomy. The objective of this study was to evaluate and compare the surgical outcome, postoperative morbidity, in-hospital mortality and survival between D2 gastrectomy with traditional D1 gastrectomy.

**METHODS**

**Patient selection**

The study involved retrospective analysis of prospectively maintained data of operated gastric cancer patients who underwent surgery between January 2016 to December 2021 and fulfilled the eligibility criteria. The study was conducted in the Department of Surgical Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar Kashmir, a tertiary care referral hospital with regional cancer centre. A total of 98 patients were enrolled in the study. Eligibility criteria were a histologically proven adenocarcinoma of the stomach without evidence of distance metastasis, age younger than 85 years, and in this study operated cases of carcinoma stomach patients were classified into two groups on the basis the of type of lymphadenectomy performed: D2 lymphadenectomy (n=52) and D1 lymphadenectomy (n=46). A standardized D1 or D2 lymphadenectomy with spleen/pancreas preservation was performed according to surgeon preference. D1 or D2 was performed by specialists trained in upper gastrointestinal surgery. The patients in the two groups were matched for age, gender and stage. Sample size calculations were created on a previous literature survey which indicated that the 5-year survival rate of D1 resection was likely to be 20%, and is found to improves to approximately to 60% with D2 gastrectomy. The statistical power was calculated using the `nQuery Advisor` statistics package (Statistical solutions, Stonehill corporate Center, USA).

**Operative procedure**

According to the Japanese gastric cancer treatment guidelines 2014 (version 4), the Japanese gastric cancer association (JGCA) defined the extent of lymphadenectomy according to the type of gastrectomy. In case of total gastrectomy, lymph nodes dissected in D1 include nodes in stations 1 to 7; D2 includes nodes in D1 stations plus 8a, 9, 10, 11p, 11d, and 12a. lymph node dissection in Station 10 may be avoided. While for subtotal gastrectomy, distal gastrectomy includes lymph node dissection in D1 including nodes in stations 1, 3, 4sb, 4d, 5, 6 and 7; D2 includes dissection of nodes in D1 stations plus 8a, 9, 11p, and 12a.

Chemotherapy was given to all patients postoperatively after surgery. Chemo protocol consists of 8 cycles of capecitabine with oxaloplatin.

**Data collection**

Preoperative demographic data included age, gender. Pathological data included tumor location, depth of tumor (T), nodal status (N), tumor differentiation type (well, moderate, poor) and tumor stage (TNM). Staging was done according to the American Joint Committee on Cancer (AJCC) 7th edition staging system. Operative data comprised of gastrectomy type (total, partial, subtotal) location (proximal, distal), lymphadenectomy type (D1, D2), blood loss during surgery, and lymph node yield. Postoperative data included postoperative complications graded according to the Clavien-Dindo classification, hospital stay, in hospital death, median survival. Hospital mortality was defined as postoperative death of any cause within 30 days, death within same hospital stay.

**Follow up**

Patients were followed up every 3 months after surgery for 2 years and every 6 months beyond two years. Baseline investigations, CA19-9, CEA levels were done. CECT abdomen was done yearly for first three years. The two groups were compared with respect to postoperative...
complications, morbidity, mortality as well as the survival etc.

Statistical analysis

The association between two categorical variables was assessed using either the chi-square test or Fisher’s exact test. To compare quantitative (continuous) variables between two groups, the two-sample t-test was applied. Survival rates were estimated using the Kaplan-Meier analysis. All statistical tests applied were two-tailed, and a p≤0.05 was considered statistically significant. Statistical analyses were performed using the Statistical Product and Service Solutions (SPSS), version 20.0, for Windows (SPSS Inc., Chicago, IL).

RESULTS

Demographic and clinicopathological characteristics of patients are presented in Table 1. The two groups were well balanced as there was no significant difference in baseline data. The age and gender distribution of the patients was matched in both groups. A total of ninety-eight patients were recruited in this study (Table 1). D1 group consisted 35 male and 11 female patients, while the D2 group consisted of 39 male and 13 female patients. Mean age of male patients in D2 group was (61.05±11.26) Range (40-80) and mean age of females in D2 group was 59.76±12.37 (Range 40-80). Mean age of male patients in D1 group was 60.10±10.14 and mean age of females in D1 group was (58.74±11.20). In both groups majority of patients were elderly males with mean age of 61 years. Male female ratio was 3:1 in both the groups. There was no significant difference in terms of age or gender between D1 and D2 groups (p>0.05) (Table 1). Of the 98 patients, 46 underwent a D1 lymphadenectomy and 52 underwent D2 lymphadenectomy. Most common tumour location was antropyloric, 60% in D2 and 65% in D1 group. In our study 90% of patients were having (T3, T4) tumors in both groups. In D2 group 75% have (N2, N3) nodal involvement. Partial/subtotal gastrectomy was commonly done operation in both groups 67% in D2 and 71% in D1. The mean number of harvested lymph nodes (LN) was (7±1.9) in the D1 group compared to (27.6±10.1) the D2 group. These figures were statistically significant (p=0.001). Average blood loss during operation was (390.23±37.51 ml) in D2 group vs (377.20±35.36 ml) in D1 group. Mean operative time was (190±28.1 min) in D2 group vs (130±20.4 min) in D1 group (Table 2). Average hospital stay was (9±1.39 days) in D2 group vs (8.6±1.13 days) in D1 group (Table 2).

Post-operative morbidity and mortality

There was no difference in postoperative complications between two groups in our study depicted in Table 3. 1 patient each group had duodenal stump leaks, which was managed conservatively, anastomotic leaks in each group were managed conservatively and 2 patients in each groups had collections, managed by percutaneous drainage. None of the patients required re exploration. There was no in hospital mortality or within 30 days of discharge from hospital in both groups. 90% of patients were followed up to death or 3 years.

Table 1: Demographic and clinicopathological characteristics of patients undergoing gastrectomy with D1 or D2 gastrectomy.

| Parameters            | Group | D2 (%) | D1 (%) | P value |
|-----------------------|-------|--------|--------|---------|
| Age (years)           | <50   | 11 (21.1) | 9 (19.56) | 0.84 |
|                       | ≥50   | 41 (78.8) | 37 (80.43) | |
| Mean age (years)      | Male  | 61.05±11.26 | 60.10±10.14 | 0.95 |
|                       | Female | 59.76±12.37 | 58.74±11.20 | 0.94 |
| Gender                | Male  | 39 (75) | 35 (76.08) | 0.9 |
|                       | Female | 13 (25) | 11 (23.91) | 0.74 |
| Smoking status        | Yes   | 30 (57.69) | 28 (60.86) | 0.83 |
|                       | No    | 22 (42.30) | 18 (39.13) | 0.83 |
| Tumor location        | Antropyloric | 31 (59.61) | 30 (65) | 0.83 |
|                       | Body  | 06 (11.53) | 4 (8.6) | 0.83 |
|                       | GE-Junction | 15 (28.84) | 12 (26.08) | 0.83 |
| Type of gastrectomy   | Distal Partial | 18 (34.61) | 25 (54.34) | 0.21 |
|                       | Sub-total | 17 (32.69) | 8 (11.29) | 0.21 |
|                       | Total   | 08 (15.38) | 6 (13.04) | 0.21 |
|                       | Proximal | 07 (13.46) | 7 (13.46) | 0.21 |
|                       | Iverlewis | 01 (1.92) | - | 0.21 |
|                       | Orringer | 01 (1.92) | - | 0.21 |
| Staging               | I/II   | 04 (7.69) | 5 (10.86) | 0.73 |
|                       | III    | 48 (92.30) | 41 (89.13) | 0.73 |
| No. of nodes retrieved| <20   | 15 (28.84) | 44 (95.65) | 0.001 |
|                       | ≥20   | 37 (71.15) | 2 (4.34) | 0.001 |

Continued.
Parameters | Group | D2 (%) | D1 (%) | P value
--- | --- | --- | --- | ---
T level | T1 | 03 (5.76) | 2 (4.34) | 0.91 | 06 (11.53) | 4 (8.69) | 0.91 | 17 (32.69) | 14 (30.43) | 0.91 | 26 (50.0) | 26 (56.52) | 0.91
N category | N0 | 05 (9.61) | -- | 0.91 | 8 (15.38) | -- | 0.91 | 14 (26.92) | -- | 0.91 | 25 (48.07) | -- | 0.91
Differentiation | Well diff. | 18 (34.6) | 15 (32.60) | 0.85 | 28 (53.8) | 27 (51.9%) | 0.85 | 6 (11.53) | 4 (8.69) | 0.85

Table 2: Operative parameters of D2 and D1 gastrectomy patients.

Operative parameters | D2 | D1 | P value
--- | --- | --- | ---
Mean blood loss (ml) | 390.3±37.51 | 377.20±35.36 | 0.081
Mean operative time (min) | 190±28.1 | 130±20.4 | 0.001
Average no of nodes retrieved | 27.6±10.1 | 7±1.9 | 0.001
Mean hospital stay (days) | 9±1.39 | 8.6±1.13 | 0.12

Table 3: Complications of D2 vs D1 gastrectomy.

Post-operative complications | D2, n=52 (%) | D1, n=46 (%) | P value
--- | --- | --- | ---
Atelectasis | 10 (19.2) | 8 (17.39) | 0.84
Consolidation | 3 (5.76) | 2 (4.34) | 0.76
Surgical site infection (SSI) | 8 (15.38) | 6 (13.04) | 0.77
Duodenal leak | 1 (1.92) | 1 (2.17) | 0.93
Intraabdominal collections | 2 (3.57) | 2 (4.34) | 0.91
Anasomotic leaks | 2 (3.57) | 1 (2.17) | 0.64
Bleeding | 1 (1.92) | 1 (2.17) | 0.93
DVT | 3 (5.76) | 2 (4.34) | 0.76
In hospital death | Nil | Nil |

Survival analysis

In D2 group the mean follow-up was 21.81±10.51 months and in D1 group it was 16.6±4.9 mo. The median survival was 26 months for the D2 and 19 months for the D1 group (p≤0.01). The length of survival in D2 group was significantly higher than in D1 group (Figure 1). Twenty-eight patients (53%) in the D2 and 15 patients (32%) in the D1 group were alive at last follow-up.

![Survival proportions: Survival of Data 1](image)

Figure 1: Kaplan-Meier survival curve.

DISCUSSION

Lymph node involvement is one of the strongest predictors of survival in gastric cancer. Studies have demonstrated the importance of both the numerical and anatomic extent of lymph node assessment in its impact on proper identification of nodal metastases as well as an important factor in achieving an R0 resection.20 A number of studies including clinical trials have clearly demonstrated that within the same TNM-stage, the greater the number of lymph node assessed the better the prognosis.21,22 There is now an increasing global consensus on performing a D2 lymphadenectomy for gastric cancer due to long-term results of large Western studies in conjunction with Eastern data.12,23,24 Radical gastrectomy with D2 lymphadenectomy, first presented by Japanese surgeons, provides survival advantage and is the current standard of care for nonmetastatic, respectable T3/T4 GC.12,25,26 However there is scarcity of data from Kashmir valley—a high incidence area of gastric cancer regarding the outcome of D2 gastrectomy.5 In this study we did a direct comparison between D1 and D2 gastrectomy to analyze the clinical outcome and survival of D2 vs D1 gastrectomy. Our study revealed an improved survival of patients undergoing D2 dissection.
compared to D1 gastrectomy (median survival 26 months for D2 group vs 19 months for the D1 group (p≤0.01). In a recent retrospective study conducted on 533 gastric cancer patients, the median survival by stages IIb and IIIc were 28.0 and 14.8 months and D2-Lymph node dissection appeared as the major prognostic indicator of survival. These findings are consistent with our results since most of our patients (90%) presented with the pathological stage III. Several other studies have also reported potential survival benefits from D2 dissection. The DGCT and MRC trials and few other studies failed to show any benefit for a D2 dissection after 5 years. This might be explained by scantiness of pretrial surgical training and the subsequent increased morbidity and mortality. Numerous studies have described a close association between the number of cases treated in a hospital and outcome in the surgical treatment of cancer. An Italian trial with adequately trained surgeons showed that a D2 dissection can be performed safely in Western countries. In Europe only the long-term follow-up of the DGCT showed a decrease in cancer-related deaths after D2 dissection. Over 2/3 of patients in our series were male patients with mean age of 61 years. Male female ratio was 3:1 in both groups, which are comparable with other studies. There was no significant difference in terms of age or gender between D1 and D2 groups (p>0.05) (Table 1). The male preponderance is in line with data from the American cancer surveillance database, surveillance, epidemiology, and end results (SEER). In our study the most common tumour location in both groups was antropyloric (59.61% in D2 and 65% in D1) in both groups in contrast to earlier study conducted in year 2000 from Kashmir in which the commonest site of cancer was the body of stomach 40.7%, followed by the antrum (35.5%) suggesting a possible changing trend in the location of gastric tumor in this region. Other reports from India also suggest distal/analrous tumours as more common than proximal tumors. In keeping with other reports from India, the most of the patients in our series presented at higher disease stage/stage III (92% in D2 and 86% in D1). A similar trend was seen in other regions where population-based cancer screening is not done such as America, Europe, and China. In D2 group lymph node yield was significantly higher than in the D1 group (p<0.001).We didn’t find any significant difference in the mean blood loss during surgery in the two groups. Moreover, mean operative time was comparable in both groups. The average hospital stay was also similar in both groups. These findings were consistent with results of Shirkhande et al. There was no difference in postoperative complications between two groups in our study.

**Limitation**

The limitation of this study is that the study involved experience of a single tertiary care referral center and is subject to referral bias. Further study period was short and thus short follow-up of the patients.

**CONCLUSION**

Our study indicates that D2 gastrectomy for advanced stage II/III gastric cancer improves the survival outcome in these patients without affecting overall hospital stay, morbidity and mortality as compared to D1 gastrectomy. D2 gastrectomy should be the standard of treatment for operable gastric cancer. However further studies with larger sample size and longer follow up needs to be carried out to substantiate our findings. Surgery for GCs in high-volume centers might result in improved perioperative outcomes.

**ACKNOWLEDGEMENTS**

Author would like to thanks to department of pathology for histopathology reporting.

**Funding: No funding sources**

**Conflict of interest: None declared**

**Ethical approval: The study was approved by the Institutional Ethics Committee**

**REFERENCES**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
2. Dikshit RP, Mathur G, Mhatre S, Yeole BB. Epidemiological review of gastric cancer in India. Indian J Med Paediatr Oncol. 2011;32:3-11.
3. Sharma A, Radhakrishnan V. Gastric cancer in India. Indian J Med Paediatr Oncol. 2011;32:12.
4. Ayub SG, Ayub T, Khan SN. Epidemiological distribution and incidence of different cancers in Kashmir valley–2002-2006. Asian Pac J Cancer Prev. 2011;12(07):1867-72.
5. Khan NA, Ahmad SA, Dar NA, Masoodi SR, Lone MM. Changing Pattern of Common Cancers in the Last Five Years in Kashmir, India: A Retrospective Observational Study. Indian J Med Paediatric Oncol. 2021;42:5.
6. Stolte M. The new Vienna classification of epithelial neoplasia of the gastrointestinal tract: advantages and disadvantages. Virchows Arch. 2003442(2):99-106.
7. Maehara YOH, Okuyama T, Moriguchi S, Tsujitani S, Korenaga D, Sugimachi K. Predictors of lymph node metastasis in early gastric cancer. Br J Cancer. 1992;79(3):245-7.
8. Coburn N. Lymph nodes and gastric cancer. J Surg Oncol. 2009;99:199-206.
9. Memon MA, Subramanyya MS, Khan S, Hossain MB, Osland E, Memon B. Meta-analysis of D1 versus D2 gastrectomy for gastric adenocarcinoma. Ann Surg. 2011;253:900-11.
10. Cuschieri AWS, Fielding J, Bancewicz J, Craven J, Joy paul V, Sydes M. Patient survival after D1 and D2 resections for gastric cancer: long-term results of
the MRC randomized surgical trial. Br J Cancer. 1999;79(9–10):1522-30.
11. Hartgrink HH vVC, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, Welvaart K, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomised Dutch gastric cancer group trial. J Clin Oncol. 2004;22(11):2069-77.
12. Songun I, Putter H, Kranenbarg EM-K, Sasaki M, Van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439-49.
13. Degiuli M, Sasaki M, Ponti A, Vendrame A, Tomatis M, Mazza C et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg. 2014;101(2):23-32.
14. Ajani JA, D’Amico TA, Almhanna K. Gastric Cancer, Version 3. 2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14:1286-312.
15. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1-19.
16. Sano T, Sasaki M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg. 2017;265(2):277-83.
17. Washington K. 7th edition of the AJCC Cancer staging manual: stomach. Ann Surg Oncol. 2010;17(12):3077-9.
18. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101-12.
19. Clavien PA, Barkun J, de Oliveir ML, Vauthey JN, Dindo D, Bassi C et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187-96.
20. Biondi A, Persiani R, Cananzi F. R0 resection in the treatment of gastric cancer: room for improvement. World J Gastroenterol. 2010;16(27):3358-70.
21. Kim YJ. Is retrieval of at least 15 lymph nodes sufficient recommendation in early gastric cancer? Ann Surg Treat Res. 2014;87(4):180-4.
22. Zheng G, Feng F, Guo M. Harvest of at least 23 Lymph Nodes is Indispensable for Stage N3 Gastric Cancer Patients. Ann Surg Oncol. 2016;9.
23. Bauer KSM, Porzsolt F, Henne-Bruns D. Comparison of international guidelines on the accompanying therapy for advanced gastric cancer: reasons for the differences. J Gastric Cancer. 2015;15(1):10-8.
24. Degiuli MMG, Leo AD, D’Ugo D, Galasso E, Marrelli D, Petrioli R et al. Gastric cancer: current status of lymph node dissection. World J Gastroenterol. 2016;22(10):2875-93.
25. Shrikhande SV, Barreto SG, Talole SD, Vinchurkar K, Annaiah S, Suradkar K, et al. D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy. World J Surg Oncol. 2013;2:11-31.
26. Shrikhande SV, Shukla PJ, Qureshi S, Siddchari R, Upasani V, Ramadwar M et al. D2 lymphadenectomy for gastric cancer in Tata Memorial Hospital: Indian data can now be incorporated in future international trials. Dig Surg. 2006;23:192-7.
27. Zeng WJ, Hu WQ, Wang LW, Yan SG, Li JD, Zhao HL et al. Long term follow up and retrospective study on 533 gastric cancer cases. BMC Surg. 2014;14:29.
28. Okines A, Verheij M, Allum W, Cunningham D, Cervantes A ESMO Guidelines Working Group. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:v50-4.
29. Jiang L, Yang KY, Chen Y, Guan QL, Zhao P, Tian JH et al. Systematic review and meta-analysis of the effectiveness and safety of extended lymphadenectomy in patients with resectable gastric cancer. Br J Surg. 2014;101:595-604.
30. Bonenkamp JJ, Hermans J, Sasaki M, Van de Velde CJ, Welvaart K, Songun I et al. Dutch Gastric Cancer Group. Extended lymphnode dissection for gastric cancer. N Engl J Med. 1999;340:908-14.
31. Birkmeyer JD, Siewers AE, Finlayson EV. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128-37.
32. Degiuli M, Sasaki M, Ponti A, Italian Gastric Cancer Study Group: Br J Surg 2010;97:643–649.
33. Safaei A, Moghimi-Delkhordi B, Fatemi SR. Clinicopathological Features of Gastric Cancer: A Study Based on Cancer Registry Data. IJCP. 2009;2:67-70.
34. Sasagawa T, Solano H, Mena F. Gastric cancer in Costa Rica. Gastrointest Endosc. 1999;50:594-5.
35. Yao JC, Tseng JF, Worah S. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution’s experience over 15 years. J Clin Oncol. 2005;23:3094-103.
36. Sadjadi A, Malekzadeh R, Derakhshan MH. Cancer occurrence in Ardabil: results of a population-based cancer registry from Iran. Int J Cancer. 2003;107:113-8.
37. Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS. Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev. 2009;18:1945-52.
38. Malik GM, Mubarak M, Kadla SA, Durrani HA. Gastric cancer profile in Kashmiri population with special dietary habits. Diagn Ther Endosc. 2000;6:83-6.
39. Bhandare MS, Kumar NA, Batra S, Chaudhari V, Shrikhande SV. Radical gastrectomy for gastric cancer at Tata Memorial Hospital. Indian J Cancer. 2017;54(4):605-8.
40. Nandi A, Biswas PK, Kar M, Sinha SK. Clinicopathological profile of gastric cancer in a
tertiary care hospital in Eastern India: a prospective 2 year study. Clin Cancer Investig J. 2014;3:14-20
41. Zheng L, Wu C, Xi P, Zhu M, Zhang L, Chen S et al. The survival and the long-term trends of patients with gastric cancer in Shanghai, China. BMC Cancer. 2014;14:300.
42. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth Edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis. Cancer. 2000;88:921-32.
43. Mickevicius A, Ignatavicius P, Markelis R, Parseliunas A, Butkute D, Kiuldelis M et al. Trends and results in treatment of gastric cancer over last two decades at single East European centre: a cohort study. BMC Surg. 2014;14:98.

Cite this article as: Younis M, Yousuf A, Ahmad SN, Vane A. Comparison of D2 versus D1 gastrectomy in Kashmiri patients in a tertiary care cancer centre. Int Surg J 2022;9:xxx-xx.